Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Network Grenada.
Press releases published on October 14, 2025
Precision Neuroscience Named to Fast Company’s Next Big Things in Tech List
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), a leader in brain–computer interface (BCI) technology, has been named to Fast Company’s Next Big Things in Tech 2025 award list. Fast Company recognized Precision …
BVI’s FINEVISION® HP Gains FDA Approval, Ushering in a New Era of Advanced Trifocal IOLs for U.S. Patients
Milestone strengthens the company’s leadership in advanced IOL innovation FINEVISION HP, with millions of implantations worldwide, will now be available to U.S. patients Proprietary design features anchor the launch of BVI’s expanded U.S. IOL portfolio …
Diginex Launches diginexGHG: AI-Powered Platform Revolutionizing Carbon Accounting Amid Surging Global Regulations and Market Growth
LONDON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Diginex Limited (NASDAQ: DGNX) (“Diginex”), a leading provider of Sustainability RegTech, is launching diginexGHG an AI-automated Corporate Carbon Footprint (CCF) solution certified according to Greenhouse Gas …
Nasdaq Grants AGM Group Holdings Inc. Continued Listing on The Nasdaq Stock Market
HONG KONG, Oct. 14, 2025 (GLOBE NEWSWIRE) -- AGM Group Holdings Inc. (“AGM Holdings” or the “Company”) (NASDAQ: AGMH), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, today …
Xtract One Announces Fiscal 2025 Annual and Fourth Quarter Conference Call
TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience …
Aanastra Inc Announces Presentations of Preclinical Data at Upcoming Conferences in Support of its Lead Programs for Anti-CD19 In Vivo CAR-T (AAN-14x) and In vivo Rescue of P53 Mutations in Tumors (AAN-53x)
Greater than 90% depletion of B cells within 12 hours of a single dose of AAN-14x Multiple redosing of AAN-14x at desired intervals with no evidence of hepatic or other toxicity Remarkable tumor regressions with AAN-53x across a broad range of P53 mutated …
Humanoid Global Announces $2.0 Million Special Warrant Financing
Vancouver, BC, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering …
ZenaTech Strengthens Drone as a Service (DaaS) Business for Government and Aviation Markets by Signing an Offer to Acquire a Second Jacksonville, Fla. Land Survey Firm
VANCOUVER, British Columbia, Oct. 14, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), …
Veteran Marketing Executive Russ Hannig Joins SponsorCX as COO Amid Rapid Growth
LEHI, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- SponsorCX, the fast-growing leader in sponsorship management, today announced the appointment of Russ Hannig as Chief Operating Officer, effective immediately. The addition underscores SponsorCX’s commitment to …
Bitcoin Bancorp Announces FINRA Completion of Corporate Name Change to Bitcoin Bancorp and New Trading Symbol “BCBC”
LAS VEGAS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Bitcoin Bancorp. (“Bitcoin Bancorp” or the “Company”), formerly Bullet Blockchain, Inc. and trading under the symbol (OTC: BULT), today announced that FINRA has confirmed and completed the Company’s corporate …
BlossomHill Therapeutics Announces Upcoming Poster Presentation on Phase 1/2 SOLARA Trial of BH-30643, a First-in-class, Macrocyclic OMNI-EGFR™ Inhibitor, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced that preliminary findings from the dose …
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to …
Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference London – 14 October 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announced that …
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a Dermatologic Rare Disease Panel at the …
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical …
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
CHATHAM, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that …
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral …
Pi Named a TIME Best Invention of 2025 in Logistics
SAN FRANCISCO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Pi, the agentic AI platform built to transform source to pay operations, has been named to TIME’s list of Best Inventions of 2025. Pi is recognized in the Logistics category for its ability to automate spend …
Frontier Medicines Announces Third Precision Oncology Development Candidate
- FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, targeting the largest genetic drivers of cancer - - Potential as a monotherapy and as a foundational treatment when used in …
Nusano and Ariceum Therapeutics Announce Multi-Isotope Supply Agreement
WEST VALLEY CITY, Utah and BERLIN, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, and Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in …